HHS Says Wellness Peptides Will Become Widely Available by Prescription
Temporary Prescription Access
HHS announced Wednesday that compounding pharmacies may temporarily make six peptides available with prescriptions. The agency said the policy is intended to address risks from black-market products and provide patients with another option.
The rules require prescriptions tailored to individual patients, traceable ingredients, quality checks and safety reports. HHS said these measures are intended to hold compounders accountable.
No FDA Approval Granted
HHS stressed that the policy does not amount to FDA approval or establish that the peptides are safe and effective. The agency said the safeguards do not replace evidence from clinical testing.
Peptides are a broad class of molecular structures. Some synthesized medicines, including insulin and GLP-1 drugs, have FDA approval after clinical trials, but the article says there are no published trials showing the specific peptides newly available are effective in humans for any condition.
Earlier FDA Action
In 2023, the FDA classified 19 peptides as unsafe to compound. HHS Secretary Robert F. Kennedy Jr. has previously said that action was illegal.
Key points
- HHS will temporarily allow prescriptions for six peptides compounded by pharmacies.
- The policy requires individualized prescriptions, traceable ingredients, quality testing and safety reporting.
- HHS says the change does not establish FDA approval or clinical safety and effectiveness.
- An FDA panel recommended six peptides for the 503A bulks list in July.